HTB South

PMTCT and maternal health

Pharmacokinetics of darunavir and fosamprenavir in pregnancy

Low birth weight and preterm delivery

Hormonal contraception and HIV transmission risk

Initiation of ART during breastfeeding can induce multidrug resistance in infants

Treating children previously exposed to single dose nevirapine: update on IMPAACT P1060 and NEVEREST

Maternal risk following short course HAART

Pre-term delivery and HAART

HAART more effective than AZT monotherapy in the Botswana PMTCT programme

Lopinavir/r monotherapy for PMTCT

No evidence of increased risk of MTCT with sequential pregnancies in UK and Ireland

Recently infected women at the time of delivery have a higher rate of in-utero transmission in PEPI-Malawi

Reduced CCL22 concentrations in cervicovaginal secretions from pregnant women

Lower incidence of pregnancy in HIV-positive compared to HIV-negative women in the Women’s Interagency HIV Study

The impact of antiretroviral treatment on fertility intentions in South Africa

Efavirenz versus nevirapine based first line treatment in a South African cohort

Impact of antiretroviral PMTCT prophylaxis regimens on subsequent maternal disease progression in Kesho Bora

Birth outcomes with antiretroviral exposure

Efavirenz-based regimens among women of reproductive age receiving ART in Johannesburg

Pregnancy outcomes in women exposed to efavirenz and nevirapine in Cote d’Ivoire

Cotrimoxazole with or without sulfadoxine-pyrimethamine reduces malaria in pregnant women

Test and treat for all pregnant women in low and middle income countries?

OCTANE 2: nevirapine and lopinavir/r are similar when used with tenofovir and FTC in treatment-naïve women

HIV incidence and retesting in pregnancy

Efavirenz use in pregnancy and birth outcomes

Pregnancy outcomes in women using non-AZT HAART in Europe

When should HAART be initiated in pregnancy to achieve an undetectable viral load?

Pregnancy outcomes in infants exposed to maternal antiretrovirals in utero

Maternal TB, HIV and pregnancy

TMC278 did not show teratogenic potential in animal models

Etravirine pregnancy data from five cases: no dose adjustment required

Pregnancy not nevirapine associated with risk of hepatotoxicity in large cohort comparison

Birth defects following efavirenz exposure in a South African Hospital

South African 2008 antenatal survey results

Treating children previously exposed to single dose nevirapine

Reducing HIV transmission during breastfeeding

PEPI Malawi: transmission rates by maternal CD4 count

Low transmission rates and favourable pregnancy outcomes reported in DREAM

Pregnancy rates and outcomes among women in the DART trial

Pregnancy outcomes in HAART exposed infants in Johannesburg

Efavirenz conceptions in Soweto

Impact of regimen and duration of therapy on risk of mother-to-child HIV transmission in Johannesburg

A cost-effectiveness analysis of the OCTANE trial

Pharmacokinetics of atazanavir/ritonavir during pregnancy

The PEARL study

Presentation with late stage HIV in women diagnosed during pregnancy

A CYP2B6 haplotype influences nevirapine plasma concentrations following a single dose to reduce mother to child transmission

Population pharmacokinetic model of nevirapine maternal to infant transfer through breastfeeding

Pregnancy, family planning, and HIV acquisition in HPTN 039

Effect of single dose nevirapine on subsequent nevirapine-containing HAART: long term outcomes

High rates of HIV acquisition in pregnancy and post partum in Francistown, Botswana

Risk factors for adverse pregnancy outcomes in Botswana

The Antiretroviral Pregnancy Registry: individual drug safety reports on health of infants exposed to ARVs during pregnancy

Antiretroviral Pregnancy Registry finds no increase in congenital anomalies with exposure to tenofovir

No association between maternal antiretrovirals in pregnancy and congenital anomalies

Pharmacokinetics of saquinavir/ritonavir in pregnancy

HAART use in pregnancy and preterm delivery and low birth weight

Tenofovir safe in pregnancy in macaque model

Antiretroviral therapy in pregnant women and pregnancy outcomes in Abidjan, Cote D’Ivoire

Predictors of mother to child transmission among women initiating HAART in pregnancy in a South African cohort

Tenofovir plus FTC reduce NNRTI resistance following single dose nevirapine

Response to treatment after single dose nevirapine exposure in women

Response to treatment after single dose nevirapine exposure in infants

Infant prophylaxis for postnatal transmission

Post navigation